Clinical Trial

Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding

Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of…

2 months ago

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be approximately$10 billion globally1Rosh Pina,…

2 months ago

Sitero Acquires StudyOS and Launches SiteroAI, Becoming the Industry’s First Truly AI-Powered CRO

MIAMI, Nov. 3, 2025 /PRNewswire/ -- Sitero, a technology-enabled Clinical Research Organization (CRO), today announced it has acquired the AI…

2 months ago

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and…

2 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…

2 months ago

Hoggan Scientific Extends Free Warranty Coverage From One Year to Three Years to Thank Customers

Company Extending Warranty as a Promise of Quality and a Thank You to Customers. SALT LAKE CITY, UTAH / ACCESS…

2 months ago

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has…

2 months ago

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…

2 months ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma,…

2 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the…

2 months ago